Following previous work on the potential risk of acute liver failure associated with quinolone antibiotics, RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski evaluated the potential risk of retinal detachment (RD) associated with these medications.
Although no cases of RD were linked to quinolones in clinical trials, some reports of RD were noted in the US FDA Adverse Event Reporting System in conjunction with systemic use of quinolone antibiotics. Analysis of electronic health records from over 500 US healthcare institutions revealed elevated but non-significant risks in African Americans (ciprofloxacin and levofloxacin), those aged 56–70 years old (moxifloxacin), and women (ciprofloxacin).
The authors noted that these suggestions of increased risk observed in some population subgroups warrant further investigation.
Posted in RSI News
More RSI News
RSI launches Global Risk Census
Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…
Read News ItemUS FDA FAERS and quinolones
Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…
Read News ItemAdvancing Toxicity Testing webinar
The Center for Alternatives to Animal Testing and the Animal-Free Safety Assessment recently held their annual meeting on advancing toxicity testing in the 21st century…
Read News ItemUSC appoints Dr. Mattison distinguished professor
Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…
Read News Item